Patents by Inventor Raymond J. Andersen
Raymond J. Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130131167Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.Type: ApplicationFiled: January 6, 2011Publication date: May 23, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20130109758Abstract: This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: January 6, 2011Publication date: May 2, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20120244632Abstract: The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).Type: ApplicationFiled: March 30, 2012Publication date: September 27, 2012Applicant: NEURODYN, INC.Inventors: Christopher Ariel SHAW, Raymond J. ANDERSEN, David E. WILLIAMS, Jaswinder BAINS
-
Patent number: 8148336Abstract: The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitosterol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).Type: GrantFiled: June 29, 2006Date of Patent: April 3, 2012Assignee: Neurodyn, Inc.Inventors: Christopher Ariel Shaw, Raymond J Andersen, David E Williams, Jaswinder Bains
-
Publication number: 20110230556Abstract: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: July 2, 2009Publication date: September 22, 2011Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E, Williams, Mike Leblanc
-
Publication number: 20110230539Abstract: Compounds having a structure of Formula (A) are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are provided. Uses of compounds having a structure of Formula (F) for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: August 24, 2009Publication date: September 22, 2011Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc, Lu-Ping Yan
-
Patent number: 7799776Abstract: Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.Type: GrantFiled: July 13, 2005Date of Patent: September 21, 2010Assignee: The University of British ColumbiaInventors: Raymond J. Andersen, Alban Pereira, Xin-Hui Huang, Grant Mauk, Eduardo Vottero, Michel Roberge, Aruna Balgi
-
Publication number: 20090042868Abstract: Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.Type: ApplicationFiled: July 13, 2005Publication date: February 12, 2009Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Raymond J. ANDERSEN, Alban PEREIRA, Xin-Hui HUANG, Grant MAUK, Eduardo VOTTERO, Michel ROBERGE, Aruna BALGI
-
Publication number: 20080255090Abstract: Antimitotic compounds and salts are provided in which the compound has the structure (formula (I)): wherein X and Y are substituted or unsubstituted and are selected from carbon atoms and atoms of groups 15 and 16 of the periodic table; Z is selected from N—R, O and S; U is selected from CR1, N, NH, NR, S and O, R1, R2, and R3 are independently selected from H, NH2, NHR, NR2, SH, SR, SiR3, OH, OR, F, CI, Br, I, ?O, ?S and R; W is selected from O, S, and H2; R4 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NR2 and halide; R is selected from H, substituted or unsubstituted aryl, and substituted or unsubstituted 1 to 20 carbon linear, branched, or cyclic, saturated or unsaturated alkyl, in which alkyl carbon atoms are replaced by 0 to 10 oxygen, 0 to 10 sulphur, and 0 to 10 N atoms; and wherein bonds to carbon atoms or to any of X, Y, Z and U are saturated or unsaturated; and providing that when W is H2, R4 is not H, OH, or unsubstituted phenyl.Type: ApplicationFiled: September 15, 2004Publication date: October 16, 2008Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Raymond J. Andersen, Michel Roberge, Emiliano Manzo
-
Patent number: 7067494Abstract: This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. C-11 to C-12 is an ideal location for conjugating functional moieties to the eleutherobin pharmacophore without significant loss of antimitotic activity. Moieties that may be conjugated at C-11 include those intended to increase the solubility of the pharmacophore, to facilitate drug formulation, or to facilitate in vivo delivery or targeting.Type: GrantFiled: June 25, 2002Date of Patent: June 27, 2006Assignee: The University of British ColumbiaInventors: Raymond J. Andersen, Michel Roberge, Robert A. Britton, E. Dilip De Silva
-
Publication number: 20040266700Abstract: This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. C-11 to C-12 is an ideal location for conjugating functional moieties to the eleutherobin pharmacophore without significant loss of antimitotic activity. Moieties that may be conjugated at C-11 include those intended to increase the solubility of the pharmacophore, to facilitate drug formulation, or to facilitate in vivo delivery or targeting.Type: ApplicationFiled: April 7, 2004Publication date: December 30, 2004Inventors: Raymond J Andersen, Michel Roberge, Robert A. Britton, E. Dilip De Silva
-
Patent number: 6812037Abstract: Antimitotic terpenoid compounds including sarcodictyin A and as eleutherobin may be obtained from organisms of the order Gorgonacea. Methods of preparing such compounds provided, as are novel antimitotic diterpene compounds having formula (I).Type: GrantFiled: November 7, 2002Date of Patent: November 2, 2004Assignee: The University of British ColumbiaInventors: Raymond J. Andersen, Michel Roberge, Bruno Cinel
-
Patent number: 6790829Abstract: Several cyclic decapeptides having antibiotic activity are disclosed. The decapeptides are active against both gram positive and gram negative bacteria.Type: GrantFiled: September 29, 1998Date of Patent: September 14, 2004Assignees: SeaTek Marine Biotechnology, Inc., University of British ColumbiaInventors: Michael T. Kelly, Raymond J. Andersen, Jeff Gerard
-
Patent number: 6784283Abstract: N- and C-modified linear cationic peptides having antibiotic activity are disclosed, which peptides are particularly active against gram positive bacteria.Type: GrantFiled: February 26, 2001Date of Patent: August 31, 2004Assignees: The University of British Columbia, Ocean Pharmaceuticals, Inc.Inventors: Raymond J. Andersen, Michael T. Kelly, Todd A. Barsby
-
Publication number: 20040048810Abstract: The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside).Type: ApplicationFiled: September 3, 2003Publication date: March 11, 2004Inventors: Christopher Ariel Shaw, Raymond J Andersen, David E Williams, Jaswinder Bains
-
Publication number: 20020035239Abstract: N— and C-modified linear cationic peptides having antibiotic activity are disclosed, which peptides are particularly active against gram positive bacteria,Type: ApplicationFiled: February 26, 2001Publication date: March 21, 2002Inventors: Raymond J. Andersen, Michael T. Kelly, Todd A. Barsby
-
Patent number: 5646138Abstract: Steroid compounds of the contignasterol family, including stereoisomers and pharmaceutically acceptable salts, as well as compositions containing these materials and a pharmaceutically acceptable carrier, are disclosed. The steroid compounds have a 3.alpha.-hydroxyl, a 4.beta.-hydroxyl, a 6.alpha.-hydroxyl, a 7.beta.-hydroxyl, a 15-ketone, a trans A/B ring juncture and a cis or trans C/D ring juncture. The compounds and compositions may be used, for example, for the prevention of inflammatory or allergic reactions, or the treatment of cardiovascular or haemodynamic disorders.Type: GrantFiled: September 5, 1995Date of Patent: July 8, 1997Assignees: University of British Columbia, University of AlbertaInventors: Raymond J. Andersen, Theresa M. Allen, David L. Burgoyne
-
Patent number: 5506221Abstract: The invention presents compounds useful for the prevention of inflammatory or allergic reaction or the treatment of cardiovascular or haemodynamic disorders having the formula: ##STR1## where R= ##STR2## where R= ##STR3## or pharmaceutically acceptable acids or salts thereof.Type: GrantFiled: April 12, 1994Date of Patent: April 9, 1996Assignees: University of British Columbia, University of AlbertaInventors: Raymond J. Andersen, Theresa M. Allen, David L. Burgoyne
-
Patent number: 5106969Abstract: 5-Methylimidazo[4,5-e]-1,2-thiazin-4(5-H)-one, having the structure ##STR1## a cytotoxic metabolite of the marine sponge Neamphius huxleyi, has been isolated from the sponge by extraction and chromatography.Type: GrantFiled: April 11, 1991Date of Patent: April 21, 1992Assignees: Cornell Research Foundation, Inc., The University of Alberta, The University of British ColumbiaInventors: Raymond J. Andersen, Theresa M. Allen, E. Dilip de Silva, Julie S. Racok, Jon Clardy, Linda S. Brinen